Publication | Closed Access
Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.
176
Citations
0
References
1991
Year
UrologyOncologyLatency PeriodChemoprevention StrategyMedicineSynthetic RetinoidPharmacotherapyAnti-cancer AgentPrimary Prostate CancerProstatic DiseasePharmacologyTumor MicroenvironmentCancer ResearchEndocrine-related Cancer
We report for the first time that a synthetic retinoid, N-(4-hydroxyphenyl)retinamide, can prevent the development of both primary and metastatic tumors in an animal model of metastasizing primary prostate cancer. Prostatic adenocarcinomas were induced in high incidence in Lobund-Wistar rats by initiation with methylnitrosourea i.v. and promotion with testosterone. Feeding of N-(4-hydroxyphenyl)retinamide to these rats during the latency period markedly diminished the final incidence of both primary and metastatic prostate carcinomas.